Person:
Furie, Barbara

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Furie

First Name

Barbara

Name

Furie, Barbara
Author's Publications: search.filters.isAuthorOfPublication.3690ef77-1b35-426c-8924-ed8edb8eec71

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Compounds targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria
    (2015) Landeta, Cristina; Blazyk, Jessica L.; Hatahet, Feras; Meehan, Brian M.; Eser, Markus; Myrick, Alissa; Bronstain, Ludmila; Wakabayashi, Shoko; Arnold, Holly; Ke, Na; Rubin, Eric; Furie, Barbara; Furie, Bruce; Beckwith, Jon; Dutton, Rachel; Boyd, Dana
    In bacteria, disulfide bonds confer stability on many proteins exported to the cell envelope or beyond. These proteins include numerous bacterial virulence factors. Thus, bacterial enzymes that promote disulfide bond formation represent targets for compounds inhibiting bacterial virulence. Here, we describe a novel target- and cell-based screening methodology for identifying compounds that inhibit the disulfide bond-forming enzymes E. coli DsbB (EcDsbB) or M. tuberculosis VKOR (MtbVKOR). MtbVKOR can replace EcDsbB although the two are not homologues. Initial screening of 51,487 compounds yielded six specifically inhibiting EcDsbB. These compounds share a structural motif and do not inhibit MtbVKOR. A medicinal chemistry approach led us to select related compounds some of which are much more effective DsbB inhibitors than those found in the screen. These compounds inhibit purified DsbB and prevent anaerobic E. coli growth. Furthermore, these compounds inhibit all but one of the DsbBs of nine other gram-negative pathogenic bacteria tested.
  • Thumbnail Image
    Publication
    Microparticles and a P-Selectin-Mediated Pathway of Blood Coagulation
    (IOS Press, 2004) Celi, Alessandro; Lorenzet, Roberto; Furie, Barbara; Furie, Bruce
  • Thumbnail Image
    Publication
    Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation
    (Nature Publishing Group, 2017) Bowley, Sheryl R.; Fang, Chao; Merrill-Skoloff, Glenn; Furie, Barbara; Furie, Bruce
    Protein disulfide isomerase (PDI), secreted by platelets and endothelial cells on vascular injury, is required for thrombus formation. Using PDI variants that form mixed disulfide complexes with their substrates, we identify by kinetic trapping multiple substrate proteins, including vitronectin. Plasma vitronectin does not bind to αvβ3 or αIIbβ3 integrins on endothelial cells and platelets. The released PDI reduces disulfide bonds on plasma vitronectin, enabling vitronectin to bind to αVβ3 and αIIbβ3. In vivo studies of thrombus generation in mice demonstrate that vitronectin rapidly accumulates on the endothelium and the platelet thrombus following injury. This process requires PDI activity and promotes platelet accumulation and fibrin generation. We hypothesize that under physiologic conditions in the absence of secreted PDI, thrombus formation is suppressed and maintains a quiescent, patent vasculature. The release of PDI during vascular injury may serve as a regulatory switch that allows activation of proteins, among them vitronectin, critical for thrombus formation.
  • Thumbnail Image
    Publication
    A specific plasminogen activator inhibitor‐1 antagonist derived from inactivated urokinase
    (John Wiley and Sons Inc., 2016) Gong, Lihu; Proulle, Valerie; Fang, Chao; Hong, Zebin; Lin, Zhonghui; Liu, Min; Xue, Guangpu; Yuan, Cai; Lin, Lin; Furie, Barbara; Flaumenhaft, Robert; Andreasen, Peter; Furie, Bruce; Huang, Mingdong
    Abstract Fibrinolysis is a process responsible for the dissolution of formed thrombi to re‐establish blood flow after thrombus formation. Plasminogen activator inhibitor‐1 (PAI‐1) inhibits urokinase‐type and tissue‐type plasminogen activator (uPA and tPA) and is the major negative regulator of fibrinolysis. Inhibition of PAI‐1 activity prevents thrombosis and accelerates fibrinolysis. However, a specific antagonist of PAI‐1 is currently unavailable for therapeutic use. We screened a panel of uPA variants with mutations at and near the active site to maximize their binding to PAI‐1 and identified a potent PAI‐1 antagonist, PAItrap. PAItrap is the serine protease domain of urokinase containing active‐site mutation (S195A) and four additional mutations (G37bR–R217L–C122A–N145Q). PAItrap inhibits human recombinant PAI‐1 with high potency (K d = 0.15 nM) and high specificity. In vitro using human plasma, PAItrap showed significant thrombolytic activity by inhibiting endogenous PAI‐1. In addition, PAItrap inhibits both human and murine PAI‐1, allowing the evaluation in murine models. In vivo, using a laser‐induced thrombosis mouse model in which thrombus formation and fibrinolysis are monitored by intravital microscopy, PAItrap reduced fibrin generation and inhibited platelet accumulation following vascular injury. Therefore, this work demonstrates the feasibility to generate PAI‐1 inhibitors using inactivated urokinase.